Royalty Report: Drugs, Antibody, Cancer – Collection: 238995

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Antibody
  • Cancer
  • Medical
  • Device
  • Diagnostic
  • Vaccine
  • Therapeutic
  • Pharmaceuticals
  • Pain
  • Test/Monitoring
  • Scientific & Technical Instruments
  • Semiconductors
  • Biological Materials
  • Detection
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 238995

License Grant
Licensor grants to Licensee a worldwide, exclusive sublicense under the Regents License to make, have made, use, sell, offer for sale and import the Sublicensed Products in the Sublicensed Field of Use and the Sublicensed Territory for the life of the last to expire patent under the Licensed Patent Rights.
License Property
Licensed Patent Rights shall have the same meaning as Regents Patent Rights under the Regents Option, namely

          (i)   The U.S. Continuation-in-Part application entitled 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/566,853 (U.C. Case No. B96-002-2) filed on December 4, 1995, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the University of California at Berkeley and assigned to Regents, that claims priority to Serial Number 08/506,666 (U.C. Case No. B96-002-1, now abandoned) filed on July 25, 1995,

          (ii)  The U.S.. Continuation-in-Part application entitled, 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/646,605 (U.C. Case No. B96-002-3) filed May 8, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the and assigned to Regents and issued as U.S. Patent No. 5,811,097, that is a CIP of Serial Number 08/566,853, which is a U.S. CIP of 08/506,666,

          (iii) The U.S. Continuation-in-Part application entitled, 'Blockade of T Lymphocyte Down-Regulation Associated with CTLA-4 Signaling,' serial number 08/760,288 (U.C. Case No. B96-002-4) filed December 4, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel of the University of California at Berkeley and assigned to Regents,

          (iv)  PCT International Patent application, Serial Number US96/19375 filed on December 4, 1996, by Drs. James P. Allison, Dana R. Leach and Matthew Krummel and assigned to Regents (U.C. Case No. B93-002/PCT) that claims the convention priority benefits of U.S. Patent Application Serial No. 08/566,853 dating from the U.S. filing date of December 4, 1995, and U.S. Patent Application Serial No. 08/646,605 dating from the U.S. filing date of May 8, 1996, and

          (v)   All other international patents and patent applications, and/or any divisions, continuations, reissues and claims in continuations-in-part that are (a) entitled to the priority filing date of Serial Numbers 08/506,666, 08,566,853, 08/646,605 or 08/760,288 and (b) are claimed or described in Serial Numbers 08/506,666, 08/566,853, 08/646,605 or 08/760,288.

Sublicensed Products means within the Sublicensed Field of Use  

(i)   Any product produced using a Licensed Method, or for use in the practice of a Licensed Method,
(ii)  Any method, process, material or product the manufacture, use or sale of which would be an infringement of any pending claim (were it to issue) or issued claim of the Licensed Patent Rights, or
(iii) Any material, method, process or product, or part thereof, that
      (A) Is covered by a valid claim of any issued, unexpired patent within Licensed Patent Rights. A claim within the Licensed Patent Rights shall be presumed to be valid unless and until it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken, or
      (B) Is covered by any claim being prosecuted in a pending application directed to the Invention (were it to issue).

Invention means the inventions described in 'Blockade of T-Lymphocyte Down-Regulation Associated with CTLA-4 Signaling' as described in Regents Case No. B96-002.

Field of Use
Sublicensed Field of Use means use of the Sublicensed Products that are antibodies (including without limitation, bispecific antibodies, single chain antibodies and/or immunoconjugated antibodies) for all human therapeutic uses permitted by the Regents License.

IPSCIO Record ID: 249703

License Grant
The University grants the Israeli Licensee, a license under the Licensed Patents and Technology in the Licensed Field of Use to make, use, offer for sale, sell and import Licensed Products in the Licensed Territory.
License Property
HCV Monoclonal Antibodies Recognizing Divergent HCV Genotypes

Licensed Patents means any Letters Patent issued upon Universitys U.S. Patent Application, Serial Number 09/430489, filed October 29, 1999, continuation-in-part US Serial Number 09/728720 filed December 21, 2000, and/or any additional patent applications, divisions, continuations, foreign applications, counterparts or reissues of any of the foregoing.

Licensed Products means any product or part thereof in the Licensed Field of Use, the manufacture, use, offer for sale, sale or import of which
(a) Is covered by a valid claim of an issued, unexpired Licensed Patent (Valid Claim) directed to the Inventions. A claim of an issued, unexpired Licensed Patent shall be presumed to be valid unless and until it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken;
(b) Is covered by any claim being prosecuted in a pending application directed to the Inventions; or
(c) Incorporates any of the Technology.

Licensed Antibodies are the E2 Antibodies CBH2, CBH4D, CBH4B, CBH4G, CBH 5 (Antibody 65), CBH7, CBH8C, CBH8E, CBH9, CBH11, and, CBH17.  And the E1 Antibodies H111, and, H114.

Field of Use
The Licensed Field of Use means use of the Licensed Patents for human therapeutics other than active immunization.

Ab65 is a human monoclonal antibodies for the treatment of chronic HCV.

IPSCIO Record ID: 25850

License Grant
The University granted the Licensee an exclusive license to  make, have made, use, sell, offer to sell, import, have imported, and otherwise exploit Licensed Products and to practice Licensed Methods.  The inventions, generally characterized as High Dose Capsaicin Relieves Neuropathic Pain (or High Dose Capsaicin for Neuropathic Pain) UCSF Case No. SF00-056.
License Property
Patent Rights means the Regents’ interest in any subject matter claimed in or covered by any of the following Pending U.S. Patent Application Serial No. 08/746,207 entitled Therapeutic Method with Capsaicin and Capsaicin Analogs filed November 6, 1996, the continuation-in-part U.S. Patent Application Serial No. 08/990,633 entitled Transdermal Therapeutic Device and Method with Capsaicin and Capsaicin Analogs filed December 15, 1997 and assigned to The Regents; pending PCT Patent Application Serial No. PCT/US98/25794 of the same title, filed December 8, 1998 and assigned to The Regents; and continuing applications thereof including divisions, substitutions, continuation-in-part applications (but only to the extent however, that claims in the continuation-in-part applications are entitled to the priority filing date of the foregoing applications); any patents issuing on said applications including reissues, reexaminations and extensions; and any corresponding foreign applications or patents based on said applications.
Field of Use
The rights granted apply to the healthcare industry.  Field of Use means all fields and uses.

IPSCIO Record ID: 279313

License Grant
University hereby grants and Licensee hereby accepts an Exclusive license under the Licensed Patents and Licensed Materials to make, have made, import, use, lease, sell and offer for sale and otherwise commercialize and exploit Licensed Products in the Licensed Territory, and practice any method process or procedure within the Licensed Patents in the Licensed Territory.  Said license is Exclusive, including the right to sublicense  in the Licensed Field of Use for a term commencing as of July 1, 1997 and ending on the expiration of the last to expire of the Licensed Patent(s).  University shall have the right to practice the Invention(s) and use the Technology for its own bona fide research, including sponsored research and collaborations. University shall have the right to publish any information included in Licensed Materials and Licensed Patent(s).
License Property
Licensed Product(s) means any product or part thereof in the Licensed Field of Use, the manufacture, use, or sale of which

(a)I s covered by a valid claim of an issued, unexpired Licensed Patent(s) directed to the Invention(s). A claim of an issued, unexpired Licensed Patent(s) shall be presumed to be valid unless and until it has been held to be invalid or unenforceable by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken or is disclaimed, or rejected or found invalid or unenforceable in a reissue application or re- examination proceeding or otherwise;
  
(b) Is covered by any claim being prosecuted in a pending application directed to the Invention(s); or

(c) Incorporates any of the Licensed Materials.

Licensed Patent(s) means any (i) U.S. patent application Serial Number 270,631 filed July 1, 1994 (issued on July 22, 1997 as U.S. Patent Number 5,650,135), (ii) all divisions, substitutions, and continuations in whole or part of any of the preceding, (iii) all foreign patent applications corresponding to or claiming priority from (including International Application Number PCT/US95/15040 and all national applications claiming priority therefrom), and (iv) all U.S. and foreign patents issuing on any of the preceding, including patents of addition, reexaminations, reissues and extensions.

5,650,135 – Non-invasive localization of a light-emitting conjugate in a mammal

Licensed Materials means those biological materials listed, and such other agreed materials as University may provide to Licensee during the term of this Agreement, which shall be added.
– Individual components of light systems (Vectors, genes and gene fragments)
– Bacteria
– Tumor cells
– Indicator cells for HIV
– Transgenic mouse lines

Field of Use
Licensed Field of Use means all uses.

IPSCIO Record ID: 329718

License Grant
Licensor hereby grants to Licensee
(A) an exclusive, royalty-bearing right and license, with the right to grant sublicenses as set forth in this Agreement, under the Licensor Technology, the Licensor Collaboration Technology and the Joint Collaboration Technology, in each case solely to  (1) sell, offer to sell, import, use, and otherwise Commercialize Non-Co-Promoted Products (other than MDX-1379) for any purpose in the Field in the United States; and
(2) sell, offer to sell, import, use and otherwise Commercialize Products for any purpose in the Field in the Royalty Territory; including, in each case ((1) and (2)), for use as monotherapy or for use together or in combination with Agents, other Immunotherapeutic Agents, or other vaccines, biologics or compounds; (3) sell, offer to sell, import, use and otherwise Commercialize MDX-1379 for all uses permitted by the PHS License for use in the Field in the Royalty Territory; and (4) make and have made Non-Co-Promoted Products (other than MDX-1379), Products and MDX 1379 for use in the activities set forth in this Agreement.

(B) a co-exclusive (with Licensor and its Affiliates), royalty-bearing right and license, with the right to grant sublicenses as set forth in this Agreement, under the Licensor Technology, the Licensor Collaboration Technology and the Joint Collaboration Technology, in each case solely to (1) sell, offer to sell, import, use and otherwise Commercialize Products (other than Non-Co-Promoted Products) for any purpose in the Field in the United States, including in each case for use as monotherapy or for use together or in combination with each Agent with respect to which the Co-Promotion Product is Developed in accordance with this Agreement; and (2) sell, offer to sell, import, use and otherwise Commercialize MDX-1379 for all uses permitted by the PHS License for use in the Field in the United States (but which license shall be exclusive if MDX-1379 is a Non-Co-Promoted Product); and
(3) make and have made Products and MDX-1379 (other than Non-Co-Promoted Products) for use in the activities set forth in this Agreement.

License Property
MDX-1379 means that certain gp100 peptide vaccine being Developed by Licensor as of the Execution Date for use together, or otherwise in combination, with MDX-010 for the treatment of metastatic melanoma.

MDX-010 is a fully human antibody against human CTLA-4, a molecule on T cells that is believed to be responsible for suppressing the immune response. MDX-010 also has the potential to enable the immune systems of cancer patients to more effectively fight tumors.

Lead Antibody means MDX-010, which has the amino acid sequences for CDR 1, 2 and 3 of the heavy chain variable region as Previously Disclosed.

U.S. Patent No. 5,811,097 – Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
U.S. Patent No. 5,855,887 – Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
U.S. Patent No. 6,051,227 – Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling

Antibody means any antibody, or fragment thereof, whether human, humanized, chimeric, murine or from any other source (and including bispecific antibodies, single chain antibodies, and immunoconjugated antibodies), that (a) has been raised, engineered or otherwise optimized to bind specifically and directly to the Target (whether exclusively or in addition to any other target such Antibody may modulate), and (b) once bound to the Target, has antagonistic activity against or otherwise blocks the immunosuppressive signaling of the Target.  For clarification, (x) any antibody or fragment thereof, whether human, humanized, chimeric, murine or from any other source (and including bispecific antibodies, single chain antibodies, and immunoconjugated antibodies) that is Derived from an Antibody, binds specifically and directly to the Target, and otherwise meets the requirements of clause (b) above, shall be an Antibody for purposes of this Agreement and (y) any fusion protein comprised of a fragment of an Antibody and that uses such fragment in order to bind to the Target shall be considered an Antibody for purposes of this Agreement.  For clarification, the Lead Antibody is an Antibody.  For the avoidance of doubt, those fusion proteins known as CTLA4-Ig and LEA-29Y shall not be considered Antibodies for purposes of this Agreement.

Licensor Non-Collaboration Technology means (a) any and all Information, Materials and inventions (i) conceived, discovered, developed or otherwise made, solely by or on behalf of Licensor or its Affiliates or, to the extent permitted under the applicable sublicense agreement, its sublicensees (other than Licensee and its Affiliates), or (ii) acquired or otherwise used (but only to the extent Controlled) by Licensor or its Affiliates, in each case ((i) and (ii)), after the Execution Date and during the term of this Agreement, that are necessary or reasonably useful in the Development, Commercialization, manufacture or use of MDX-1379, an Antibody, Product or Non-Antibody Substance, whether or not patented or patentable, but excluding any (u) Excluded Technology, (v) Licensor Pre-Existing Technology, (w) Mice-Related Technology, (x) Mice Materials, (y) Collaboration Technology and (z) any Information, Materials and inventions conceived, discovered, developed or otherwise made, by or on behalf of Licensor, its Affiliates or sublicensees in connection with the clinical trials identified in this Agreement, unless and until such activities are set forth in a Global Development Plan and Budget and Licensee reimburses Licensor for Licensee’s share of such Development Costs as provided in this Agreement (collectively, “Licensor Non-Collaboration Know-How”), and (b) Patents and other intellectual property rights with respect to the Information, Materials and inventions described in clause (a) above (collectively, “Licensor Non-Collaboration Patents”); provided, however, upon termination of this Agreement pursuant to this Agreement with respect to a Product or MDX-1379, Licensor Non-Collaboration Technology shall be limited to (1) Licensor Non-Collaboration Know-How and Licensor Non-Collaboration Patents with respect to such Product or MDX-1379 that are in existence as of the date of termination, and (2) those Patents that are filed thereafter to the extent that they claim Licensor Non-Collaboration Know-How included in clause (1) above.  For purposes of this definition, the determination of whether Information, Materials and inventions are conceived, discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) therein, shall be made in accordance with Applicable Law in the United States.

Commercialize means to promote, market, distribute, sell (and offer for sale or contract to sell) or provide product support for a Product or MDX-1379.

Field of Use
Field of use is for the treatment of metastatic melanoma (cancer) by the development and commercialization of an antibody-based product incorporating MDX-010 as the sole active ingredient or for use together, or otherwise in combination, with MDX-1379 (gp-100) or with certain other immunotherapeutic agents. The Lead Product is for use in the first Cancer Indication.

Cancer means any type of cancer in any cell or organ in a human body, including any Core Cancer.

IPSCIO Record ID: 27499

License Grant
The University hereby grants to the Licensee an exclusive license in the Field of Use, including the right to sublicense under the Patent Rights to make, have made, use, Sell, offer for Sale, import Licensed Products, and to practice the Licensed Method in the United States and in other countries where the University may lawfully grant such licenses.

The University also grant to the Licensee, so long as it retains exclusive rights under this Agreement, the right to issue Sublicenses.

License Property
Whereas, certain inventions are characterized as 'Chemical Nanowire Sensor Arrays' ('Invention');
Whereas, the Invention covered under UC Case Number 2004-177 ('Bio-receptor Embedded Conductive Polymer Nanowire Sensor Arrays');
Whereas, the Invention covered under UC Case Number 2007-108 ('Metal Nanoparticles Decorated Carbon Nanotubes for Gas Sensors');
Whereas, certain of the Inventions covered under UC Case Numbers 2010-170 ('Synthesis of Nanopeapods by Galvanic Displacement of Segmented Nanowires') and 2010-240 ('Metal and Metal Oxides Co-Functionalization SWNT's as High Performance Gas Sensors');

The License was granted within certain fields of use relating to “Bio-receptor Embedded Conductive Polymer Nanowire Sensor Arrays”, “Metal Nanoparticles Decorated Carbon Nanotubes for Gas Sensors”, the “Synthesis of Nanopeapods by Galvanic Displacement of Segmented Nanowires”, “Metal and Metal Oxides Co-Functionalization SWNT’s as High Performance Gas Sensors”, “Ultra-Sensitive Gas Sensors Based on Tellurium-Single Walled Carbon Nanotube Hybrid Nanostructures” and “Selective Nanoscale Asymmetric Gas Sensors”.

The license relates to patented and patent-pending sensor technologies based on nano materials that can detect airborne gases to the parts-per-billion (PPB) level.

'Patent Rights' means the University's interest in the Valid Claims of the United States patents and patent applications, corresponding foreign patents and patent applications and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those Valid Claims in the continuation-in-part applications that are entirely supported in the specification and entitled to the priority date of the parent application) based on the following

'Bio-receptor Embedded Conductive Polymer Nanowire Sensor Arrays' filed on October 25, 2005, United States Patent Application Serial Number 11/259,557, assigned to The Regents (UC Case Number 2004-177-2);
'Metal Nanoparticles Decorated Carbon Nanotubes for Gas Sensors' filed on September 11, 2007, United States Patent Application Serial Number 12/514,050, assigned to The Regents (UC Case Number 2007-108-2);
'Synthesis of Nanopeapods by Galvanic Displacement of Segmented Nanowires' to be filed shortly and assigned to The Regents (UC Case Number 2010-170); and
'Metal and Metal Oxides Co-Functionalization SWNT's as High Performance Gas Sensors' to be filed shortly and assigned to The Regents (UC Case Number 2010-240).

Field of Use
'Field of Use' means the use of the Licensed Products and the Licensed Methods for chemical detection using carbon nanotube-based sensory arrays. Any use of the Licensed Products for other than chemical detection is excluded from the Field of Use.

The Licensee will try to commercialize patented and patent-pending sensor technologies based on nano materials that can detect airborne gases to the parts-per-billion level to be used in air quality monitoring, explosives detection, industrial plant toxic gas detection, gaseous chemical warfare agent detection, food and agricultural safety hazard detection and other applications.

IPSCIO Record ID: 260370

License Grant
The Regents grants to the Licensee a license under its rights in and to Patent Rights to make, have made, use, Sell, offer for Sale and import Licensed Products and to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.

The Regents grants to the Licensee a license under its rights in and to Property Rights to make, have made and use the Biological Materials to make, have made, use, Sell, offer for Sale and import Licensed Products, or to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.

License Property
The Certain inventions are generally characterized as
—  High Affinity Human Antibodies to Novel Tumor Antigens;
—  Bi-specific Single Chain Fv scFv Antibody Molecule; and,
—  Human Erb-B Antibodies.
Field of Use
The Field of Use means use as a therapeutic or diagnostic in humans. The Field of Use specifically excludes providing Licensed Services to third parties; the Sale, transfer, lease, exchange or other disposition or provision of Biological Materials, other than as incorporated in Licensed Products for Sale or as expressly permitted in this Agreement; the making, using or Selling of Biological Materials or Licensed Products for use in drug discovery or as a research reagent (other than for the development of Licensed Products);  the making, using or Selling of Non-Patent Products; and (v) all other uses and applications of Biological Material or Licensed Products, except as expressly permitted in this Agreement.

IPSCIO Record ID: 279976

License Grant
Licensor hereby grants to Licensee through the period and subject to the limitation on the number of Antigens, the right to receive for each Antigen designated by Licensee, a nonexclusive, worldwide license under the Licensor Licensed Patents to make, have made, use, import, offer to sell and sell Antibodies pursuant to a Licensor License Agreement. This right shall not extend to the Licensor Named Antigens.  The rights of Licensee under the Licensor License Agreements shall include the right to grant sublicenses for Antibodies in accordance with the terms of the applicable Licensor License Agreement.  Each license elected by Licensee hereunder shall be pursuant to a separate Licensor License Agreement and effective as of the date of execution by both parties.
License Property
Antigen means a target molecule, usually a protein, to which an Antibody specifically binds and includes all epitopes on that target molecule.

Antibody means any antibody directed against an Antigen and shall include, without limitation, monospecific and bispecific antibodies (but a separate license shall be required for the antigen involved for each arm of  a  bispecific antibody); less than full-length antibody forms such as Fv, Fab, and F(ab)2; single-chain antibodies; and antibody conjugates bound to a toxin, label or other moiety.  The term 'Antibody' shall include any and all such constructs directed against any particular Antigen.

(a) U.S. Patent No. 4,816,567 and the claims relating to chimeric antibodies found in patents or patent applications arising from divisionals, continuations or continuations-in-part of any application from which U.S. Patent No. 4,816,567 claims priority or any substitute applications therefor, any patent issued with respect to any such patent application, any reissue, extension or patent term extension of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent  as well as the foreign counterparts of the foregoing and any and all reissues, reexaminations or extensions of the foregoing (but in any event excluding U.S.S.N. 07/205,419 and foreign counterparts thereof) ('Chimera Patents') and (b)  any patent issuing based on U.S.S.N. 07/205,419 (a continuation of the application maturing into U.S. Patent No. 4,816,567) relating to the coexpression of immunoglobulin chains in recombinant host cells, as well as the divisionals, continuations or continuations-in-part of such U.S.S.N. 07/205,419.

4,816,567 – Recombinant immunoglobin preparations

Field of Use
Herceptin[R] (trastuzumab) is a humanized anti-HER2 antibody for the treatment of breast cancer.

IPSCIO Record ID: 364010

License Grant
Licensor hereby grants to Licensee and exclusive license. Subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.  

Licensor also hereby grants to Licensee an exclusive license to make. use. and/or sell the Licensed Materials in the Territory for Field of Use.  At Licensee’s request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

Licensor grants to Licensee a six (6) month exclusive option to negotiate a worldwide royalty-bearing, exclusive license with right to sublicense for any Improvement.

License Property
The Podack Cancer Vaccine (UM97-14) technology shall mean the technology relating to a cell-based vaccine for treating cancer patients utilizes human cancer cells that have been engineered to secrete gp96.  The presently preferred version of the vaccine uses the AD100 human lung adrenocarcinoma cell line transfected with constructs that encode III.A-AI and gp96-Ig (heat shock protein gp96 fused to Fe region of IgGI).  In a presently preferred protocol, NSCLC patients are intradermermally administered several injections of 5×107 vaccine cells each at two week intervals.

Licensed Product shall mean any product or part thereof which
(a) is covered in whole or in part by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights
(b) is manufactured by using a process which is covered in whole or in party by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights or
(c) incorporated or comprises the Podack Cancer Vaccine (UM97-14) or the cell line “AD100-gp96/III.A”.

Patent Rights shall mean the following United States Patent applications  U.S. provisional patent application serial number 60/075.358 entitled “Modified Heat Shock Protein-antigenic Peptide Complex” and filed on February 20, 1998  U.S. patent application serial number 09 253.439 entitled “Modified Heat Shock Protein-Antigenic Peptide Complex” and filed on February 19, 1999  U.S. patent  application serial number 11/878.460 entitled “Recombinant Cancer Cell Secreting Modified Heat Shock Protein-antigenic Peptide Complex” and filed on July 24, 2008  all United States patents and foreign patents and patent applications based on these U.S. applications  all divisionals, continuations of the foregoing  and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. provisional patent applications serial number 60/075.358.  U.S. Patent application serial number 09 253.439, or U.S. patent application serial number 11/878.460 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.  â€œPatent Rights” shall not include Excluded Patent Rights.

Licensed Materials shall mean any modified AD100 cell lines that have been engineered to secrete gp96.

Field of Use
Field of Use is for treating cancer patients and shall mean all human healthcare and research applications.

IPSCIO Record ID: 115864

License Grant
The University grants to the Licensee a worldwide license under Licensors Patent Rights to make, have made, use, sell, and distribute Licensed Products and to practice Licensed Method.  The Licensor also grants to the Licensee the right to issue sublicenses to third parties to make, have made, use, sell, and distribute Licensed Products and to practice the Licensed Method.
License Property
The license is for certain inventions, generally characterized as a noninvasive continuous iontophoretic blood monitor/drug delivery system.  Patents relates to devices for iontophoretic non-invasive sampling of substances.

The Licensed Product is any material that is either covered by Licensor’s Patent Rights or any product manufactured using the Licensed Method, in either event to the extent the manufacture, use or sale of which in a particular country infringes an unexpired valid claim of a patent or a pending claim of a patent application under Patent Rights in that country in which such patent has issued or application is pending.

The Licensed Method is any method that is covered by the claims of Licensor’s Patent Rights in the country in which such method is used, or the use or practice of which would constitute, but for the license granted to the Licensee pursuant to this Agreement, an infringement of any unexpired, valid issued claim or pending claim under Patent Rights in that country in which the Licensed Method is used or practiced.

(a) U.S. Patent Application serial no. 150,159, filed 29 Jan 88,(abandoned) by Dr. Richard Guy, et al., and assigned to The Regents;

(b) U.S. Patent Application serial no. 299,397, filed 24 Jan 89, as a continuation-in-part application of (a), (abandoned) by Dr. Richard Guy, et al., and assigned to The Regents;

(c) U.S. Patent Application serial no. 771,483, filed 04 Oct 91, as a continuation-in-part of (b) (now allowed) by Dr. Richard Guy, et al., and assigned to The Regents;

(d) U.S. Patent No. 5,279,543, issued 18 Jan 94, which was a file wrapper continuation application of (b), by Dr. Richard Guy, et al, and assigned to The Regents; and continuing applications thereof including divisions and substitutions but including continuation-in-part applications only to the extent that the claim was supported in the original disclosure; any patents issuing on said application or continuing applications including reissues and extensions; and any corresponding foreign applications or patents.

Field of Use
This agreement pertains to drug delivery systems.  The Licensee, GlucoWatch system is designed to measure glucose frequently, automatically and non-invasively through the ease and convenience of a device worn like a wristwatch.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.